Pharmaceutical trade group sues Trump administration

• The lawsuit targets Health Secretary Robert F. Kennedy Jr., HHS, CMS Administrator Meme Oz, and other federal health officials in U.S. District Court for the District of Columbia
• The GLOBE rule's final version was published last week, detailing how international price benchmarking would be integrated into Medicare Part B for hospital-administered drugs
• PhRMA claims the Trump administration's effort to tie U.S. drug prices to lower overseas costs exceeds the government's legal authority

Summary: Pharmaceutical Trade Group Sues Trump Administration Over Drug Pricing Rule

The Pharmaceutical Research and Manufacturers of America (PhRMA), the pharmaceutical industry's leading lobby group, filed a lawsuit on Wednesday, October 7, challenging the Trump administration's GLOBE rule, which aims to reduce U.S. drug prices by benchmarking them against lower international costs.

Key Details:

The GLOBE rule seeks to establish a "most favored nation" pricing system for hospital drugs under Medicare Part B, basing U.S. prices on those paid in comparable countries. The final version of the rule was published last week, detailing how this international pricing benchmark would be integrated into the Medicare program.

PhRMA argues the rule represents illegal government overreach and filed suit in the U.S. District Court for the District of Columbia. Defendants include Health Secretary Robert F. Kennedy Jr., the Department of Health and Human Services, CMS Administrator Meme Oz, and other officials from the Centers for Medicare & Medicaid Services (CMS) and its Center for Medicare and Medicaid Innovation (CMMI).

Market Implications:

This lawsuit represents a major confrontation between the pharmaceutical industry and federal efforts to control healthcare costs. The outcome could significantly impact:

• Drug pricing strategies for Medicare Part B hospital medications
• Pharmaceutical company revenues and profit margins
• The broader debate over U.S. drug prices, which are typically higher than in other developed nations
• Future government attempts to regulate pharmaceutical pricing

The legal challenge underscores the industry's strong opposition to international price benchmarking, which could substantially reduce revenues if implemented. The case will likely have far-reaching implications for healthcare policy and pharmaceutical sector valuations.